The Centers for Disease Control and Prevention (CDC) has announced a new funding opportunity, RFA-DP-24-031, titled “Epidemiologic Cohort Study of Interstitial Cystitis.” This program, with an estimated total funding of $4.15 million, aims to follow a cohort of interstitial cystitis (IC) patients over time to define demographic and clinical patterns of the condition and document its impact on health. The initiative seeks to translate scientific knowledge on IC into practical public health actions.
Eligible applicants for this cooperative agreement include a broad range of entities, from educational institutions to government agencies and nonprofits. The program intends to support patient strategies for improving quality of life, provider awareness and education, and the medical and self-management of IC. It also focuses on strengthening clinical, community, and public health linkages and targeting groups disproportionately impacted by IC. This funding opportunity highlights the CDC’s commitment to understanding and addressing the challenges posed by IC, a condition that affects millions yet remains under-researched.
Opportunity ID: 348751
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-DP-24-031 |
| Funding Opportunity Title: | Epidemiologic Cohort Study of Interstitial Cystitis |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | |
| Expected Number of Awards: | 1 |
| CFDA Number(s): | 93.945 — Assistance Programs for Chronic Disease Prevention and Control |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Nov 15, 2023 |
| Last Updated Date: | Nov 15, 2023 |
| Original Closing Date for Applications: | Feb 09, 2024 Electronically submitted applications must be submitted no later than 11:59 pm ET on the listed application due date. |
| Current Closing Date for Applications: | Feb 09, 2024 Electronically submitted applications must be submitted no later than 11:59 pm ET on the listed application due date. |
| Archive Date: | Feb 11, 2024 |
| Estimated Total Program Funding: | $ 4,150,000 |
| Award Ceiling: | $900,000 |
| Award Floor: | $800,000 |
Eligibility
| Eligible Applicants: | Independent school districts Small businesses County governments Public and State controlled institutions of higher education City or township governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education State governments Special district governments Native American tribal governments (Federally recognized) For profit organizations other than small businesses Public housing authorities/Indian housing authorities Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | This NOFO is open competition |
Additional Information
| Agency Name: | Centers for Disease Control and Prevention – ERA |
| Description: | The purpose of the research NOFO is follow a cohort of interstitial cystitis (IC) patients over time, define the demographic and clinical patterns of IC, and document its impact on the health of affected people. In addition, the focus of this NOFO will include translating the scientific knowledge on IC extracted from previously funded and other studies so it can be used to support public health action, including patient strategies for improving quality of life, provider awareness and education, and medical and self-management of IC; strengthen clinical, community, and public health linkages; and target groups disproportionately impacted by IC. |
| Link to Additional Information: | |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact: Natalie Brown
fmc7@cdc.gov |